Ahlgren G - Search Results

1

Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: introducing the Prostate Cancer Consortium in Europe.

Fizazi K, Abrahamsson PA, Ahlgren G, Bellmunt J, Castellano D, Culine S, de Wit R, Gillessen S, Gschwend JE, Hamdy F, James N, McDermott R, Miller K, Wiegel T, Wirth M, Tombal B. Fizazi K, et al. Among authors: ahlgren g. Eur Urol. 2015 May;67(5):904-12. doi: 10.1016/j.eururo.2014.08.076. Epub 2014 Sep 11. Eur Urol. 2015. PMID: 25218582

2

The risk of malignancy in the surgical margin at radical prostatectomy reduced almost three-fold in patients given neo-adjuvant hormone treatment.

Hugosson J, Abrahamsson PA, Ahlgren G, Aus G, Lundberg S, Schelin S, Schain M, Pedersen K. Hugosson J, et al. Among authors: ahlgren g. Eur Urol. 1996;29(4):413-9. doi: 10.1159/000473789. Eur Urol. 1996. PMID: 8791047 Clinical Trial.

3

A DNA cytometric proliferation index improves the value of the DNA ploidy pattern as a prognosticating tool in patients with carcinoma of the prostate.

Ahlgren G, Lindholm K, Falkmer U, Abrahamsson PA. Ahlgren G, et al. Urology. 1997 Sep;50(3):379-84. doi: 10.1016/S0090-4295(97)00223-9. Urology. 1997. PMID: 9301701

4

Hormonal treatment before radical prostatectomy: a 3-year followup.

Aus G, Abrahamsson PA, Ahlgren G, Hugosson J, Lundberg S, Schain M, Schelin S, Pedersen K. Aus G, et al. Among authors: ahlgren g. J Urol. 1998 Jun;159(6):2013-6; discussion 2016-7. doi: 10.1016/S0022-5347(01)63230-0. J Urol. 1998. PMID: 9598509 Clinical Trial.

5

Tumor cell proliferation in prostate cancer after 3 months of neoadjuvant LHRH analogue treatment is a prognostic marker of recurrence after radical prostatectomy.

Ahlgren G, Pedersen K, Lundberg S, Aus G, Hugosson J, Abrahamsson PA. Ahlgren G, et al. Urology. 1999 Aug;54(2):329-34. doi: 10.1016/s0090-4295(99)00107-7. Urology. 1999. PMID: 10443734 Clinical Trial.

6

Evaluation of DNA ploidy combined with a cytometric proliferation index of imprints from core needle biopsies in prostate cancer.

Ahlgren G, Falkmer U, Gadaleanu V, Abrahamsson PA. Ahlgren G, et al. Eur Urol. 1999 Oct;36(4):314-9. doi: 10.1159/000020011. Eur Urol. 1999. PMID: 10473991

7

Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment.

Ahlgren G, Pedersen K, Lundberg S, Aus G, Hugosson J, Abrahamsson PA. Ahlgren G, et al. Prostate. 2000 Mar 1;42(4):274-9. doi: 10.1002/(sici)1097-0045(20000301)42:4<274::aid-pros4>3.0.co;2-r. Prostate. 2000. PMID: 10679756 Clinical Trial.

8

Palliative radiation with a radiolabeled diphosphonate (rhenium-186 etidronate) in patients with hormone-refractory disseminated prostate carcinoma.

Tennvall J, Abrahamsson PA, Ahlgren G, Darte L, Flodgren P, Garkavij M, Strand SE. Tennvall J, et al. Among authors: ahlgren g. Scand J Urol Nephrol. 2000 Jun;34(3):188-93. doi: 10.1080/003655900750016571. Scand J Urol Nephrol. 2000. PMID: 10961473

9

The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population.

Giwercman YL, Abrahamsson PA, Giwercman A, Gadaleanu V, Ahlgren G. Giwercman YL, et al. Among authors: ahlgren g. Eur Urol. 2005 Oct;48(4):679-85. doi: 10.1016/j.eururo.2005.06.011. Eur Urol. 2005. PMID: 16039774

10

A plea for surgical lymph node staging in advanced prostate cancer.

Liedberg F, Ahlgren G, Bratt O, Bendahl PO. Liedberg F, et al. Among authors: ahlgren g. Eur Urol. 2013 Feb;63(2):409-10. doi: 10.1016/j.eururo.2012.10.041. Epub 2012 Nov 2. Eur Urol. 2013. PMID: 23137942 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

53 results

Search Page